Congressional hearings on drug shortages continue due in part to continued efforts of the American Society of Clinical Oncology (ASCO) and the medical community to raise awareness and seek solutions to this crisis. On Nov. 30, the U.S. House of Representatives Oversight and Government Reform Subcommittee on Health Care, District of Columbia, Census and the National Archives convened a hearing on the issue.
Michelle Hudspeth, MD, director of the Pediatric Hematology/Oncology Division at the Medical University of South Carolina, testified that “the current situation is nothing short of a massive national emergency” and that the shortages were severely impacting cancer care.
Dr. Hudspeth also discussed why she felt the reimbursement model created through the Medicare Modernization Act of 2003 has helped lead to the shortages.
Read the full report at: http://tinyurl.com/7xta8rv
Source: Oncology Business Review; ASCO
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More